Date:2/29/2012

1)(768,642)(712,343)Cash flows from financing activities:Proceeds from initial public offering of common stock--85,000,000Costs of initial public offering--(7,479,011)Proceeds from borrowings on long-term debt--18,000,000Principal payments on note payable(5,333,333)(12,666,667)(5,000,000)Net borrowings on line of credit3,034,000--Costs of financing for long-term debt and credit facility(17,637)(110,000)(189,660)Payments made in connection with repurchase of common shares(4,247,440)(4,846,791)(27,295,808)Proceeds from exercise of stock options629,8651,362,760175,089Excess tax benefit derived from exercise of stock options2,355,3453,874,9663,968,894Net cash (used in) provided by financing activities(3,579,200)(12,385,732)67,179,504Net increase (decrease) in cash and cash equivalents4,705,176(12,807,712)66,872,131Cash and cash equivalents, beginning of year65,893,97078,701,68211,829,551Cash and cash equivalents, end of year$   70,599,146$   65,893,970$   78,701,682Supplemental disclosure of cash flow information:Cash paid during the year for:Interest$
91,410$
814,373$
77,387Income taxes304,48052,136196,187Noncash investing and financing activities:Change in unpaid invoices for purchases of intangibles97,806--Reclass of redeemable common stock to (from) equity-1,930,000(1,930,000)Deferred financing costs--335,075
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia